Question explored with the scientific record
What is primary aldorteronism
Primary aldosteronism is a condition where the adrenal glands make too much aldosterone, a hormone that tells the kidneys to hold onto salt and water while dumping potassium. This drives up blood pressure and can damage the heart and blood vessels beyond what the high pressure alone would do.
The evidence here shows this is not rare. Among people with resistant hypertension (blood pressure that stays high on three or more drugs), about 7 to 20 in 100 have primary aldosteronism [3]. Even in general hypertension, the rate is about 6 in 100 [4]. The condition is frequently missed because the screening test (the aldosterone-to-renin ratio) has poor sensitivity—around 35% at standard cutoffs—meaning most cases slip through [5]. A newer approach using a dexamethasone-suppressed test found the true prevalence in unselected hypertensives may be closer to 30% [5].
The harm is real. In a large Japanese registry of 2,582 patients, 9.4% already had cardiovascular disease at diagnosis, mostly stroke [2]. A plasma aldosterone level above 125 pg/mL roughly doubled the odds of having had a cardiovascular event [2]. Unilateral disease (one adrenal gland making the excess) carried higher risk than bilateral [2]. The condition also worsens autoimmune thyroiditis: in one case report, removing the aldosterone-producing tumor dropped thyroid antibody titers from over 3,000 to under 500 U/ml and normalized thyroid function [1].
| Group | CVD prevalence | Key risk factor |
|---|---|---|
| All PA patients | 9.4% | PAC ≥125 pg/mL (OR ~1.9) |
| Unilateral subtype | Higher than bilateral | Hypokalemia common |
| General hypertension | ~2-4% (background) | - |
My call: primary aldosteronism is a common, underdiagnosed, and damaging condition that deserves far more aggressive screening than it gets. Confidence: high.
Sources used 5
-
Coexistence of primary aldosteronism and Hashimoto’s thyroiditis
In a 36-year-old woman, laparoscopic removal of an aldosterone-producing adrenal tumor was followed by improved thyroid function, reduced thyroid antibody titers, and lower monocyte and lymphocyte cytokine release, suggesting primary aldosteronism may exacerbate Hashimoto's thyr…
DOI: 10.1007/s00296-011-2032-6 -
Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism
This multicenter Japanese JPAS study quantified the prevalence of cardiovascular disease in primary aldosteronism, identified hypokalemia and unilateral subtype as key risk factors for CVD, and found a threshold plasma aldosterone concentration (PAC) of 125 pg/mL associated with…
DOI: 10.1161/HYPERTENSIONAHA.117.10263 -
Resistant Hypertension
This 2014/2018-era review synthesizes current knowledge on resistant hypertension, detailing its definitions, prevalence, secondary etiologies (eg, obstructive sleep apnea and primary aldosteronism), diagnostic approaches, and evidence-based management strategies ranging from li…
DOI: 10.1001/jama.2014.5180 -
Primary Aldosteronism
A comprehensive, expert-level review of primary aldosteronism (PA) covering its prevalence, pathophysiology, screening, diagnosis, subtyping, treatment (MR antagonists and adrenalectomy), and cardiovascular implications, advocating expanded PA screening in hypertension and outli…
DOI: 10.1161/CIRCULATIONAHA.118.033597 -
Five Reasons for the Failure to Diagnose Aldosterone Excess in Hypertension
A critical examination of why aldosterone excess is frequently missed in hypertension, highlighting ACTH effects, test limitations, and the value of combining ACTH-suppression strategies with ARR for better detection and prevalence estimates.
DOI: 10.1055/a-1236-4869